Vascular Dynamics Inc. Appoints New CEO

Vascular Dynamics Inc. (VDI), a privately held medical device company which has developed a treatment system for the treatment of hypertension, announced the appointment of Ed Roschak as its president and chief executive officer.
 
“We are fortunate that Ed has decided to join the VDI Team as CEO. He has extensive experience in managing the IDE/PMA process with the FDA, raising capital to finance complex clinical studies, managing a rapid revenue ramp for novel, clinically superior devices and successfully guiding companies through the exit process,” commented Michael Henson, VDI Chairman. “These skills make Ed an excellent fit for Vascular Dynamics as we begin the CALM 2 IDE-approved, pivotal clinical study in the U.S., maximize the value of the Expedited Access Pathway for the VDI Mobius system granted to us by the FDA, and prepare for worldwide commercialization.”
 
Mr. Roschak joins VDI from NuVasive Specialized Orthopedics, where he served as CEO upon the successful acquisition of his previous company, Ellipse Technologies Inc., where he was president and CEO. Prior to his seven years at Ellipse, he held a variety of positions at Broncus Technologies Inc., an interventional pulmonology startup company focused on asthma and emphysema. Asthmatx Inc. was spun-out of Broncus and acquired by Boston Scientific. He also held engineering roles with increasing responsibility at Hewlett-Packard, Origin Medsystems and Krebs Engineers.  Mr. Roschak is a named inventor on 30 granted patents, more than 60 patent applications published in the U.S., and more worldwide. He has also been published in the Journal of Thoracic Surgery. Mr. Roschak earned his MBA from the University of Oregon Executive Program and earned a BS in mechanical engineering from University of California, Santa Barbara.
 
“The use of VDI’s MobiusHD device in the first 68 patients with resistant hypertension has produced outstanding results, exceeding anything published to date by alternative devices. I am excited to join the VDI team as we begin to execute our FDA-approved pivotal trial. If we are successful, MobiusHD has the potential to become a revolutionary treatment option for patients suffering from this life-threatening disease,” said Roschak.